Trial ID 21346

NCT02635672
clinicaltrials.gov ID
USOR ID: 21346 Phase I
An Open-Label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as monotherapy or in combination with KEYTRUDA® (pembrolizumab) in Subjects with Advanced Cancer

Trial ID 20289

NCT04254107
clinicaltrials.gov ID
USOR ID: 20289 Phase I
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies

Trial ID 11282

NCT01716806
clinicaltrials.gov ID
USOR ID: 11282 Phase II
A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Trial ID 18263

NCT04116437
clinicaltrials.gov ID
USOR ID: 18263 Phase II
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib 

Trial ID 20133

NCT04824092
clinicaltrials.gov ID
USOR ID: 20133 Phase III
A Phase III, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in high-risk patients with previously untreated Diffuse Large B-Cell Lymphoma

Trial ID 21195

NCT04981795
clinicaltrials.gov ID
USOR ID: 21195 Phase N/A
Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second- or third-line therapy and not receiving autologous stem cell transplant

Trial ID

NCT05471843
clinicaltrials.gov ID
Phase N/A

Trial ID 19109

NCT03460977
clinicaltrials.gov ID
USOR ID: 19109 Phase I
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Trial ID

NCT02922764
clinicaltrials.gov ID
Phase I

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology